Breaking Finance News

Clearside Biomedical Inc (NASDAQ:CLSD) target price raised to $21.00, reported today by JMP Securities

Clearside Biomedical Inc (NASDAQ:CLSD) had its target bumped up to $21.00 by JMP Securities in an issued report announced 5/25/2017. The bumped up target suggests a potential upside of 1.79% based on the company's last closing price.

Yesterday Clearside Biomedical Inc (NASDAQ:CLSD) traded 2.47% higher at $7.54. The company’s 50-day moving average is $7.79 and its 200-day moving average is $7.96. The last closing price is down -6.05% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 79,558 shares of the stock traded hands, down from an average trading volume of 132,727

Recent Performance Chart

Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical Inc has with a one year low of $5.44 and a one year high of $25.08 and has a market capitalization of $0.

A total of 3 analysts have released a report on Clearside Biomedical Inc. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $19.00.

General Company Details For Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *